


# Analysis of Prazosin in Serum

Application  
Pharmaceutical  
Robert Ricker

Prazosin is a common drug administered as a blocker of alpha-adrenergic receptors. Blocking is selective for alpha-1 receptors and, therefore, reduces sympathetic activity to blood vessels without producing reflex tachycardia, and is a useful antihypertensive drug. Prazosin is especially useful for patients having asthma, lipid abnormalities, and symptomatic prostatism. Levels may be monitored to determine physiological levels in the blood stream upon treatment or misuse. On-line sample preparation/concentration using column switching enabled this analysis to be a fast, direct approach. The final analytical separation was performed using a ZORBAX SB-CN column. For details of the column switching technique visit the applications page of the ChromTech Website:

<http://www.chromtech.se/biotrap>



**Conditions:**

ZORBAX SB-CN, 4.6 x 150 mm, 5μm, Agilent P/N: 883975-905 + guard  
Mobile phase: 35% ACN and 2 mM Na octanesulfonate in 116 mM Na phosphate, pH 2.8  
F=1.0 mL/min, Det.: Fluorescence, ex = 340 nm, em = 385 nm

## Highlights

- After on-line extraction, prazosin in a 50 μL serum sample was analyzed using a ZORBAX SB-CN column.
- The analyte eluted from the ZORBAX SB-CN column with good peak shape.
- ZORBAX StableBond columns operate optimally and with excellent stability at low pH (e.g., 2.8).
- **NOTE:** For Investigational / Research only. The performance characteristic for this procedure has not been established. Not for in vitro diagnostic procedures.



Agilent Technologies

*Robert Ricker is an application chemist  
based at Agilent Technologies, Wilmington,  
Delaware.*

For more information on our products and  
services, visit our website at:  
[www.agilent.com/chem](http://www.agilent.com/chem)

Copyright© 2002 Agilent Technologies, Inc.  
All Rights Reserved. Reproduction,  
adaptation or translation without prior  
written permission is prohibited, except as  
allowed under the copyright laws.

Agilent shall not be liable for errors  
contained herein or for incidental or  
consequential damages in connection with  
the furnishing, performance, or use of this  
material.

Information, descriptions, and specifications  
in this publication are subject to change  
without notice.

Printed in the USA  
April 25, 2002  
5988-6400EN



**Agilent Technologies**